The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia

Progress in Molecular Biology and Translational Science

Volumn 106, Issue , 2012, Pages 107-142

  Juan, Wen Chun ^a   Ong, S Tiong ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Drug resistance; Leukemia stem cell; Protein phosphorylation

Indexed keywords

EID: 84857205204     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396456-4.00007-9     Document Type: Chapter

References (188)

1. T.G. Lugo, and O.N. Witte The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc Mol Cell Biol 9 1989 1263 1270 (Pubitemid 19071695)
2. B.J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood 112 2008 4808 4817
3. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, and B. Wassmann Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551 (Pubitemid 43882350)
4. M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, and R. Paquette Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541 (Pubitemid 43882349)
5. G. Saglio, A. Hochhaus, Y.T. Goh, T. Masszi, R. Pasquini, and F. Maloisel Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily Cancer 116 2010 3852 3861
6. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, and F. Cervantes Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
7. M.W. Deininger, J.M. Goldman, and J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
8. A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, and B.J. Druker Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity J Clin Invest 121 2011 396 409
9. A. Quintas-Cardama, H. Kantarjian, S. O'Brien, G. Garcia-Manero, M.B. Rios, and M. Talpaz Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia Cancer 100 2004 2592 2597 (Pubitemid 38715764)
10. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, and D.L. Jones Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 2006 9339 9344 (Pubitemid 44623625)
11. K. Naka, T. Hoshii, T. Muraguchi, Y. Tadokoro, T. Ooshio, and Y. Kondo TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia Nature 463 2010 676 680
12. G.A. Challen, and M.H. Little A side order of stem cells: the SP phenotype Stem Cells 24 2006 3 12
13. E. Nicholson, and T. Holyoake The chronic myeloid leukemia stem cell Clin Lymphoma Myeloma 9 Suppl. 4 2009 S376 S381
14. O. Hantschel, and G. Superti-Furga Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat Rev Mol Cell Biol 5 2004 33 44 (Pubitemid 38089839)
15. S. Taagepera, D. McDonald, J.E. Loeb, L.L. Whitaker, A.K. McElroy, and J.Y. Wang Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase Proc Natl Acad Sci USA 95 1998 7457 7462 (Pubitemid 28293274)
16. P. Vigneri, and J.Y. Wang Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase Nat Med 7 2001 228 234 (Pubitemid 32148491)
17. M.A. Kelliher, J. McLaughlin, O.N. Witte, and N. Rosenberg Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL Proc Natl Acad Sci USA 87 1990 6649 6653
18. V.L. Tybulewicz, C.E. Crawford, P.K. Jackson, R.T. Bronson, and R.C. Mulligan Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene Cell 65 1991 1153 1163 (Pubitemid 121001329)
19. P. Yaish, A. Gazit, C. Gilon, and A. Levitzki Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors Science 242 1988 933 935 (Pubitemid 19015255)
20. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, and J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037 (Pubitemid 32267972)
21. A.J. Finn, G. Feng, and A.M. Pendergast Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction Nat Neurosci 6 2003 717 723
22. N.P. Shah, C. Kasap, C. Weier, M. Balbas, J.M. Nicoll, and E. Bleickardt Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis Cancer Cell 14 2008 485 493
23. A.M. Pendergast, L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, and N. Li BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein Cell 75 1993 175 185 (Pubitemid 23306031)
24. R.P. Million, and R.A. Van Etten The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase Blood 96 2000 664 670 (Pubitemid 30463389)
25. C. Kardinal, B. Konkol, H. Lin, M. Eulitz, E.K. Schmidt, and Z. Estrov Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes Blood 98 2001 1773 1781
26. E.K. Thomas, J.A. Cancelas, H.D. Chae, A.D. Cox, P.J. Keller, and D. Perrotti Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease Cancer Cell 12 2007 467 478 (Pubitemid 350046406)
27. A. Sengupta, J. Arnett, S. Dunn, D.A. Williams, and J.A. Cancelas Rac2 GTPase deficiency depletes BCR-ABL + leukemic stem cells and progenitors in vivo Blood 116 2010 81 84
28. M.Y. Yang, T.C. Liu, J.G. Chang, P.M. Lin, and S.F. Lin JunB gene expression is inactivated by methylation in chronic myeloid leukemia Blood 101 2003 3205 3211
29. E. Passegue, W. Jochum, M. Schorpp-Kistner, U. Mohle-Steinlein, and E.F. Wagner Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage Cell 104 2001 21 32 (Pubitemid 32144969)
30. E. Passegue, E.F. Wagner, and I.L. Weissman JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells Cell 119 2004 431 443 (Pubitemid 39423844)
31. F. Chang, L.S. Steelman, J.T. Lee, J.G. Shelton, P.M. Navolanic, and W.L. Blalock Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention Leukemia 17 2003 1263 1293 (Pubitemid 36857335)
32. M. Notari, P. Neviani, R. Santhanam, B.W. Blaser, J.S. Chang, and A. Galietta A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation Blood 107 2006 2507 2516 (Pubitemid 43345575)
33. L. Bakiri, D. Lallemand, E. Bossy-Wetzel, and M. Yaniv Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression EMBO J 19 2000 2056 2068 (Pubitemid 30237581)
34. H. Hermeking, C. Rago, M. Schuhmacher, Q. Li, J.F. Barrett, and A.J. Obaya Identification of CDK4 as a target of c-MYC Proc Natl Acad Sci USA 97 2000 2229 2234 (Pubitemid 30134051)
35. J.W. Rooney, T. Hoey, and L.H. Glimcher Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene Immunity 2 1995 473 483
36. S.K. Chai, G.L. Nichols, and P. Rothman Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients J Immunol 159 1997 4720 4728 (Pubitemid 127471006)
37. C. Sillaber, F. Gesbert, D.A. Frank, M. Sattler, and J.D. Griffin STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells Blood 95 2000 2118 2125 (Pubitemid 30151654)
38. A. Hoelbl, B. Kovacic, M.A. Kerenyi, O. Simma, W. Warsch, and Y. Cui Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation Blood 107 2006 4898 4906 (Pubitemid 43882643)
39. R.L. Ilaria Jr., and R.A. Van Etten P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members J Biol Chem 271 1996 31704 31710 (Pubitemid 26408636)
40. A. Klejman, S.J. Schreiner, M. Nieborowska-Skorska, A. Slupianek, M. Wilson, and T.E. Smithgall The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells EMBO J 21 2002 5766 5774 (Pubitemid 35315274)
41. T. Nosaka, T. Kawashima, K. Misawa, K. Ikuta, A.L. Mui, and T. Kitamura STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells EMBO J 18 1999 4754 4765 (Pubitemid 29415529)
42. M. Horita, E.J. Andreu, A. Benito, C. Arbona, C. Sanz, and I. Benet Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL J Exp Med 191 2000 977 984
43. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501 (Pubitemid 37328931)
44. M. Sattler, M.G. Mohi, Y.B. Pride, L.R. Quinnan, N.A. Malouf, and K. Podar Critical role for Gab2 in transformation by BCR/ABL Cancer Cell 1 2002 479 492 (Pubitemid 41039128)
45. T. Skorski, A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, and J.K. Choi Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway EMBO J 16 1997 6151 6161 (Pubitemid 27458335)
46. T. Skorski, P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczak, S.C. Wen, and G. Zon Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood 86 1995 726 736
47. M.G. Kharas, J.A. Deane, S. Wong, K.R. O'Bosky, N. Rosenberg, and O.N. Witte Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells Blood 103 2004 4268 4275 (Pubitemid 38685373)
48. N.T. Ihle, and G. Powis Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Mol Cancer Ther 8 2009 1 9
49. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807 826 (Pubitemid 32295062)
50. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484 (Pubitemid 43199434)
51. A. Haghighat, S. Mader, A. Pause, and N. Sonenberg Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E EMBO J 14 1995 5701 5709
52. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945 (Pubitemid 39071573)
53. G. Thomas An encore for ribosome biogenesis in the control of cell proliferation Nat Cell Biol 2 2000 E71 E72
54. B. Raught, F. Peiretti, A.C. Gingras, M. Livingstone, D. Shahbazian, and G.L. Mayeur Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases EMBO J 23 2004 1761 1769 (Pubitemid 38649639)
55. D.D. Sarbassov, S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, and H. Erdjument-Bromage Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302 (Pubitemid 38991819)
56. R. Loewith, E. Jacinto, S. Wullschleger, A. Lorberg, J.L. Crespo, and D. Bonenfant Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 2002 457 468 (Pubitemid 35284167)
57. V. Facchinetti, W. Ouyang, H. Wei, N. Soto, A. Lazorchak, and C. Gould The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C EMBO J 27 2008 1932 1943
58. M.G. Mohi, C. Boulton, T.L. Gu, D.W. Sternberg, D. Neuberg, and J.D. Griffin Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs Proc Natl Acad Sci USA 101 2004 3130 3135 (Pubitemid 38327746)
59. N. Carayol, E. Vakana, A. Sassano, S. Kaur, D.J. Goussetis, and H. Glaser Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells Proc Natl Acad Sci USA 107 2010 12469 12474
60. L. del Peso, M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 278 1997 687 689 (Pubitemid 27464966)
61. A. Essafi, S. Fernandez de Mattos, Y.A. Hassen, I. Soeiro, G.J. Mufti, and N.S. Thomas Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells Oncogene 24 2005 2317 2329 (Pubitemid 40546691)
62. A. Hochhaus, S.G. O'Brien, F. Guilhot, B.J. Druker, S. Branford, and L. Foroni Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
63. H.M. Kantarjian, J.E. Cortes, S. O'Brien, R. Luthra, F. Giles, and S. Verstovsek Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha Blood 104 2004 1979 1988 (Pubitemid 39297846)
64. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, and F. Nicolini Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
65. R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, and C.L. Sawyers Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 2003 4701 4707 (Pubitemid 36857723)
66. G.V. Helgason, G.A. Young, and T.L. Holyoake Targeting chronic myeloid leukemia stem cells Curr Hematol Malig Rep 5 2010 81 87
67. M.W. Deininger, and T.L. Holyoake Can we afford to let sleeping dogs lie? Blood 105 2005 1840 1841 (Pubitemid 40731754)
68. M. Deininger, E. Buchdunger, and B.J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653 (Pubitemid 40446252)
69. H. Konig, T.L. Holyoake, and R. Bhatia Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606 Blood 111 2008 2329 2338 (Pubitemid 351451441)
70. H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, and T.L. Holyoake Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells Blood 109 2007 4016 4019 (Pubitemid 46641755)
71. M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, and N. Jordanides Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 2006 4532 4539 (Pubitemid 43801382)
72. S.M. Graham, H.G. Jorgensen, E. Allan, C. Pearson, M.J. Alcorn, and L. Richmond Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325
73. T.L. Holyoake, X. Jiang, H.G. Jorgensen, S. Graham, M.J. Alcorn, and C. Laird Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3 Blood 97 2001 720 728 (Pubitemid 32113406)
74. T. Holyoake, X. Jiang, C. Eaves, and A. Eaves Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia Blood 94 1999 2056 2064 (Pubitemid 29430422)
75. S.W. Lane, D.T. Scadden, and D.G. Gilliland The leukemic stem cell niche: current concepts and therapeutic opportunities Blood 114 2009 1150 1157
76. M. Konopleva, Y. Tabe, Z. Zeng, and M. Andreeff Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches Drug Resist Updat 12 2009 103 113
77. O.H. Yilmaz, R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, and H. Wu Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells Nature 441 2006 475 482 (Pubitemid 44050144)
78. J.Y. Lee, D. Nakada, O.H. Yilmaz, Z. Tothova, N.M. Joseph, and M.S. Lim mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion Cell Stem Cell 7 2010 593 605
79. M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, and J. Apperley Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
80. T.P. Hughes, A. Hochhaus, S. Branford, M.C. Muller, J.S. Kaeda, and L. Foroni Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765
81. L.C. Crossman, B.J. Druker, M.W. Deininger, M. Pirmohamed, L. Wang, and R.E. Clark hOCT 1 and resistance to imatinib Blood 106 2005 1133 1134 (author reply 1134)
82. E. Jabbour, H. Kantarjian, D. Jones, M. Talpaz, N. Bekele, and S. O'Brien Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 2006 1767 1773 (Pubitemid 44574988)
83. S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, and A. Poerio Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 2006 7374 7379 (Pubitemid 46095411)
84. J.S. Khorashad, H. de Lavallade, J.F. Apperley, D. Milojkovic, A.G. Reid, and M. Bua Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression J Clin Oncol 26 2008 4806 4813
85. A. Quintas-Cardama, H.M. Kantarjian, and J.E. Cortes Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia Cancer Control 16 2009 122 131
86. L. Luzzatto, and J.V. Melo Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells Blood 100 2002 1105 (Pubitemid 34832656)
87. T. O'Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, and J. Mestan In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505 (Pubitemid 40740783)
88. S. Branford, J.V. Melo, and T.P. Hughes Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 2009 5426 5435
89. I.J. Griswold, M. MacPartlin, T. Bumm, V.L. Goss, T. O'Hare, and K.A. Lee Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Mol Cell Biol 26 2006 6082 6093 (Pubitemid 44204527)
90. X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, and A. Eaves Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies Leukemia 21 2007 926 935 (Pubitemid 46672068)
91. D.L. White, V.A. Saunders, P. Dang, J. Engler, A.C. Zannettino, and A.C. Cambareri OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2006 697 704 (Pubitemid 44061372)
92. D.K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, and P. Dang Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications Clin Cancer Res 14 2008 3881 3888
93. K. Eechoute, A. Sparreboom, H. Burger, R.M. Franke, G. Schiavon, and J. Verweij Drug transporters and imatinib treatment: implications for clinical practice Clin Cancer Res 17 2011 406 415
94. J. Thomas, L. Wang, R.E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 2004 3739 3745 (Pubitemid 39564452)
95. F.X. Mahon, M.W. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, and J.M. Goldman Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079 (Pubitemid 30616875)
96. C.L. Abram, and S.A. Courtneidge Src family tyrosine kinases and growth factor signaling Exp Cell Res 254 2000 1 13 (Pubitemid 30066726)
97. M. Stanglmaier, M. Warmuth, I. Kleinlein, S. Reis, and M. Hallek The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains Leukemia 17 2003 283 289 (Pubitemid 36266903)
98. Y. Hu, Y. Liu, S. Pelletier, E. Buchdunger, M. Warmuth, and D. Fabbro Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia Nat Genet 36 2004 453 461 (Pubitemid 38620028)
99. N.J. Donato, J.Y. Wu, J. Stapley, G. Gallick, H. Lin, and R. Arlinghaus BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 2003 690 698 (Pubitemid 36077594)
100. J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, and Z. Peng Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood 111 2008 3821 3829
101. S.J. Kuerbitz, B.S. Plunkett, W.V. Walsh, and M.B. Kastan Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc Natl Acad Sci USA 89 1992 7491 7495
102. A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, and M.J. Ausserlechner p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa Science 302 2003 1036 1038 (Pubitemid 37386194)
103. B. Calabretta, and D. Perrotti The biology of CML blast crisis Blood 103 2004 4010 4022 (Pubitemid 38685338)
104. H.G. Wendel, E. de Stanchina, E. Cepero, S. Ray, M. Emig, and J.S. Fridman Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proc Natl Acad Sci USA 103 2006 7444 7449 (Pubitemid 43727852)
105. L. O'Connor, A. Strasser, L.A. O'Reilly, G. Hausmann, J.M. Adams, and S. Cory Bim: a novel member of the Bcl-2 family that promotes apoptosis EMBO J 17 1998 384 395 (Pubitemid 28045479)
106. F. Luciano, A. Jacquel, P. Colosetti, M. Herrant, S. Cagnol, and G. Pages Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function Oncogene 22 2003 6785 6793 (Pubitemid 37372218)
107. K.J. Aichberger, M. Mayerhofer, M.T. Krauth, A. Vales, R. Kondo, and S. Derdak Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds Cancer Res 65 2005 9436 9444 (Pubitemid 41508012)
108. J. Kuroda, H. Puthalakath, M.S. Cragg, P.N. Kelly, P. Bouillet, and D.C. Huang Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic Proc Natl Acad Sci USA 103 2006 14907 14912 (Pubitemid 44527827)
109. R. Kuribara, H. Honda, H. Matsui, T. Shinjyo, T. Inukai, and K. Sugita Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors Mol Cell Biol 24 2004 6172 6183 (Pubitemid 38891120)
110. E. San Jose-Eneriz, X. Agirre, A. Jimenez-Velasco, L. Cordeu, V. Martin, and V. Arqueros Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia Eur J Cancer 45 2009 1877 1889
111. N. Mizushima Autophagy: process and function Genes Dev 21 2007 2861 2873 (Pubitemid 350133435)
112. X.H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, and H. Hibshoosh Induction of autophagy and inhibition of tumorigenesis by beclin 1 Nature 402 1999 672 676 (Pubitemid 129516338)
113. D.C. Rubinsztein, J.E. Gestwicki, L.O. Murphy, and D.J. Klionsky Potential therapeutic applications of autophagy Nat Rev Drug Discov 6 2007 304 312 (Pubitemid 46505881)
114. Y. Mishima, Y. Terui, A. Taniyama, R. Kuniyoshi, T. Takizawa, and S. Kimura Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors Cancer Sci 99 2008 2200 2208
115. C. Bellodi, M.R. Lidonnici, A. Hamilton, G.V. Helgason, A.R. Soliera, and M. Ronchetti Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells J Clin Invest 119 2009 1109 1123
116. D.M. Virshup, and S. Shenolikar From promiscuity to precision: protein phosphatases get a makeover Mol Cell 33 2009 537 545
117. D. Perrotti, and P. Neviani Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias Cancer Metastasis Rev 27 2008 159 168
118. Q. Tian, and J. Wang Role of serine/threonine protein phosphatase in Alzheimer's disease Neurosignals 11 2002 262 269 (Pubitemid 37494393)
119. B.G. Neel, H. Gu, and L. Pao The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem Sci 28 2003 284 293 (Pubitemid 36776291)
120. Z.Q. Shi, D.H. Yu, M. Park, M. Marshall, and G.S. Feng Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity Mol Cell Biol 20 2000 1526 1536 (Pubitemid 30100172)
121. V. Cleghon, P. Feldmann, C. Ghiglione, T.D. Copeland, N. Perrimon, and D.A. Hughes Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway Mol Cell 2 1998 719 727 (Pubitemid 128378980)
122. J.M. Cunnick, S. Meng, Y. Ren, C. Desponts, H.G. Wang, and J.Y. Djeu Regulation of the mitogen-activated protein kinase signaling pathway by SHP2 J Biol Chem 277 2002 9498 9504 (Pubitemid 34953038)
123. M. Quintanar-Audelo, P. Yusoff, S. Sinniah, S. Chandramouli, and G.R. Guy Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras/extracellular signal-regulated kinase (ERK) pathway J Biol Chem 286 2011 23102 23112
124. M. Tartaglia, E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, and H. Kremer Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat Genet 29 2001 465 468 (Pubitemid 34326699)
125. K. Choong, M.H. Freedman, D. Chitayat, E.N. Kelly, G. Taylor, and A. Zipursky Juvenile myelomonocytic leukemia and Noonan syndrome J Pediatr Hematol Oncol 21 1999 523 527 (Pubitemid 30305988)
126. R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, and Z. He Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia Blood 106 2005 3142 3149 (Pubitemid 41565912)
127. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, and S.I. Wang PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947 (Pubitemid 27148818)
128. C. Peng, Y. Chen, Z. Yang, H. Zhang, L. Osterby, and A.G. Rosmarin PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice Blood 115 2010 626 635
129. A. Aggerholm, K. Gronbaek, P. Guldberg, and P. Hokland Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders Eur J Haematol 65 2000 109 113 (Pubitemid 30615084)
130. E. Sontag Protein phosphatase 2A: the Trojan Horse of cellular signaling Cell Signal 13 2001 7 16 (Pubitemid 32222967)
131. J. Ivaska, L. Nissinen, N. Immonen, J.E. Eriksson, V.M. Kahari, and J. Heino Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta Mol Cell Biol 22 2002 1352 1359 (Pubitemid 34150772)
132. X. Li, H.J. Yost, D.M. Virshup, and J.M. Seeling Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus EMBO J 20 2001 4122 4131 (Pubitemid 32751828)
133. P. Neviani, R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, and S. Liu The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 2005 355 368 (Pubitemid 41579831)
134. M.R. Junttila, P. Puustinen, M. Niemela, R. Ahola, H. Arnold, and T. Bottzauw CIP2A inhibits PP2A in human malignancies Cell 130 2007 51 62 (Pubitemid 47039258)
135. J.D. Arroyo, and W.C. Hahn Involvement of PP2A in viral and cellular transformation Oncogene 24 2005 7746 7755 (Pubitemid 41670676)
136. R. Ruediger, H.T. Pham, and G. Walter Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene Oncogene 20 2001 1892 1899 (Pubitemid 32458699)
137. C.M. Lucas, R.J. Harris, A. Giannoudis, M. Copland, J.R. Slupsky, and R.E. Clark Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression Blood 117 2011 6660 6668
138. A. Salas, S. Ponnusamy, C.E. Senkal, M. Meyers-Needham, S.P. Selvam, and S.A. Saddoughi Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A Blood 117 2011 5941 5952
139. E. Weisberg, P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan-Jacob, and A. Ray Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141 (Pubitemid 40248339)
140. A. Quintas-Cardama, and J.E. Cortes Chronic myeloid leukemia: diagnosis and treatment Mayo Clin Proc 81 2006 973 988 (Pubitemid 43993489)
141. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305
142. G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, and C. Lobo Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
143. H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, and M. Ayala Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
144. S. Chu, M. Holtz, M. Gupta, and R. Bhatia BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34 + cells Blood 103 2004 3167 3174 (Pubitemid 38451695)
145. J.V. Melo, and C. Chuah Novel agents in CML therapy: tyrosine kinase inhibitors and beyond Hematology Am Soc Hematol Educ Program 2008 2008 427 435
146. C. Chuah, D.J. Barnes, M. Kwok, A. Corbin, M.W. Deininger, and B.J. Druker Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells Leukemia 19 2005 1896 1904 (Pubitemid 41553997)
147. D.G. Peters, R.R. Hoover, M.J. Gerlach, E.Y. Koh, H. Zhang, and K. Choe Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia Blood 97 2001 1404 1412 (Pubitemid 32183766)
148. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, and P. Angibaud Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 61 2001 131 137 (Pubitemid 32095710)
149. J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, and A. Thibault Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood 101 2003 1692 1697 (Pubitemid 36237561)
150. G. Borthakur, H. Kantarjian, G. Daley, M. Talpaz, S. O'Brien, and G. Garcia-Manero Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy Cancer 106 2006 346 352 (Pubitemid 43100443)
151. M. Copland, F. Pellicano, L. Richmond, E.K. Allan, A. Hamilton, and F.Y. Lee BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood 111 2008 2843 2853
152. C. Ly, A.F. Arechiga, J.V. Melo, C.M. Walsh, and S.T. Ong Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin Cancer Res 63 2003 5716 5722 (Pubitemid 37187466)
153. S. Prabhu, D. Saadat, M. Zhang, L. Halbur, J.P. Fruehauf, and S.T. Ong A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation Oncogene 26 2007 1188 1200
154. W.G. Kaelin Jr. The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698 (Pubitemid 41486362)
155. D.A. Chan, and A.J. Giaccia Harnessing synthetic lethal interactions in anticancer drug discovery Nat Rev Drug Discov 10 2011 351 364
156. M.A. Gregory, T.L. Phang, P. Neviani, F. Alvarez-Calderon, C.A. Eide, and T. O'Hare Wnt/Ca2+/NFAT signaling maintains survival of Ph + leukemia cells upon inhibition of Bcr-Abl Cancer Cell 18 2010 74 87
157. R.T. Silver The blast phase of chronic myeloid leukaemia Best Pract Res Clin Haematol 22 2009 387 394
158. D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski Chronic myeloid leukemia: mechanisms of blastic transformation J Clin Invest 120 2010 2254 2264
159. C.G. Mullighan, C.B. Miller, I. Radtke, L.A. Phillips, J. Dalton, and J. Ma BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros Nature 453 2008 110 114 (Pubitemid 351630327)
160. J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, and B. Druker Gene expression changes associated with progression and response in chronic myeloid leukemia Proc Natl Acad Sci USA 103 2006 2794 2799
161. C.H. Jamieson, L.E. Ailles, S.J. Dylla, M. Muijtjens, C. Jones, and J.L. Zehnder Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N Engl J Med 351 2004 657 667 (Pubitemid 39063268)
162. A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, and I.G. Newton Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation Proc Natl Acad Sci USA 106 2009 3925 3929
163. K. Cramer, M. Nieborowska-Skorska, M. Koptyra, A. Slupianek, E.T. Penserga, and C.J. Eaves BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair Cancer Res 68 2008 6884 6888
164. T. Skorski BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts Leuk Lymphoma 49 2008 610 614 (Pubitemid 351517197)
165. T. Skorski Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state Leuk Lymphoma 52 Suppl. 1 2011 23 29
166. D.J. Barnes, D. Palaiologou, E. Panousopoulou, B. Schultheis, A.S. Yong, and A. Wong Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia Cancer Res 65 2005 8912 8919 (Pubitemid 41377381)
167. M. Marega, R.G. Piazza, A. Pirola, S. Redaelli, A. Mogavero, and I. Iacobucci BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients Leukemia 24 2010 1445 1449
168. B.J. Huntly, H. Shigematsu, K. Deguchi, B.H. Lee, S. Mizuno, and N. Duclos MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 6 2004 587 596 (Pubitemid 40017702)
169. A.M. Coluccia, A. Vacca, M. Dunach, L. Mologni, S. Redaelli, and V.H. Bustos Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation EMBO J 26 2007 1456 1466 (Pubitemid 46398694)
170. P. Neviani, R. Santhanam, Y. Ma, G. Marcucci, J.C. Byrd, and C.S. Chen Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph(+) chronic myelogenous leukemia (CML) CD34+/CD38 - stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL -independent signals Blood 112 2008 77 (Abstract 189)
171. T. Ueda, R. Watanabe-Fukunaga, H. Fukuyama, S. Nagata, and R. Fukunaga Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development Mol Cell Biol 24 2004 6539 6549 (Pubitemid 38944335)
172. S. Lim, T.Y. Saw, S. Chang, M. Zhang, M. Janes, D. Fruman, D. Rizzieri, S.Y. Tan, C Chuah, and S.T. Ong Targeting of a novel MNK-eIF4E-β-catenin axis in blast crisis chronic myelogenous leukemia inhibits leukemia stem cell function Blood 118 2011 21 (Abstract 963)
173. R.C. D'Angelo, and M.S. Wicha Stem cells in normal development and cancer Prog Mol Biol Transl Sci 95 2010 113 158
174. A.A. Merchant, and W. Matsui Targeting Hedgehog - a cancer stem cell pathway Clin Cancer Res 16 2010 3130 3140
175. C. Zhao, A. Chen, C.H. Jamieson, M. Fereshteh, A. Abrahamsson, and J. Blum Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia Nature 458 2009 776 779
176. C. Dierks, R. Beigi, G.R. Guo, K. Zirlik, M.R. Stegert, and P. Manley Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation Cancer Cell 14 2008 238 249
177. N.A. Riobo, K. Lu, X. Ai, G.M. Haines, and C.P. Emerson Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling Proc Natl Acad Sci USA 103 2006 4505 4510
178. A.M. Eiring, J.G. Harb, P. Neviani, C. Garton, J.J. Oaks, and R. Spizzo miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts Cell 140 2010 652 665
179. W. Pao, and V.A. Miller Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions J Clin Oncol 23 2005 2556 2568
180. M.A. Essers, S. Offner, W.E. Blanco-Bose, Z. Waibler, U. Kalinke, and M.A. Duchosal IFNalpha activates dormant haematopoietic stem cells in vivo Nature 458 2009 904 908
181. T. Sato, N. Onai, H. Yoshihara, F. Arai, T. Suda, and T. Ohteki Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion Nat Med 15 2009 696 700
182. C. Preudhomme, J. Guilhot, F.E. Nicolini, A. Guerci-Bresler, F. Rigal-Huguet, and F. Maloisel Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2010 2511 2521
183. P. Eliasson, and J.I. Jonsson The hematopoietic stem cell niche: low in oxygen but a nice place to be J Cell Physiol 222 2010 17 22
184. N.L. Komarova, and D. Wodarz Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies Cancer Res 69 2009 4904 4910
185. D. Wodarz, and N.L. Komarova Emergence and prevention of resistance against small molecule inhibitors Semin Cancer Biol 15 2005 506 514 (Pubitemid 41318049)
186. N.P. Shah, H.M. Kantarjian, D.W. Kim, D. Rea, P.E. Dorlhiac-Llacer, and J.H. Milone Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia J Clin Oncol 26 2008 3204 3212
187. L. Wang, H.L. McLeod, and R.M. Weinshilboum Genomics and drug response N Engl J Med 364 2011 1144 1153
188. D. Housman Human DNA polymorphism N Engl J Med 332 1995 318 320